Is Innospec (IOSP) Offering Value After A 16.2% One Year Share Price Decline?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

Wondering whether Innospec at around US$76.64 is offering value or just treading water? This article walks through what the current price might be telling you about the stock. The share price has moved 0.5% over the last week and 5.2% over the last month, while the 1 year return sits at a 16.2% decline. This can change how the market prices both risk and opportunity. Recent coverage has focused on how Innospec fits into the broader chemicals sector and the way investors are reassessing companies with mixed shorter term and longer term return profiles. That context helps explain why some shareholders are rethinking whether a 16.2% 1 year decline and a 18.9% 5 year decline match their view of the stock's value. Right now Innospec scores a 5 out of 6 valuation check. The rest of this article will compare different valuation approaches to that score while also pointing you to a simple framework at the end that can make sense of them all.

Find out why Innospec's -16.2% return over the last year is lagging behind its peers.

Approach 1: Innospec Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the cash the company may generate in the future and discounting those amounts back to today.

For Innospec, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month Free Cash Flow is about $69.7 million, and analysts provide explicit forecasts out to 2027, with Simply Wall St extrapolating cash flows further to 2035. Within these projections, estimated Free Cash Flow in 2035 is about $102.1 million, all expressed in US$.

Combining these discounted cash flows results in an estimated intrinsic value of around $81.57 per share. Compared with the recent share price of about $76.64, this suggests the stock is roughly 6.0% undervalued, which is a relatively small gap and indicates that the current market price is broadly aligned with this DCF estimate.

Result: ABOUT RIGHT

Innospec is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.IOSP Discounted Cash Flow as at May 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Innospec.

Approach 2: Innospec Price vs Earnings

For profitable companies, the P/E ratio is a useful way to think about value because it links what you pay per share to the earnings that each share generates. In general, higher growth expectations and lower perceived risk tend to support a higher, or more generous, P/E ratio, while lower growth expectations and higher risk tend to justify a lower one.

Story Continues

Innospec currently trades on a P/E of about 16.4x. That sits below both the Chemicals industry average P/E of roughly 28.1x and a peer group average of around 22.9x. On simple comparisons, the stock is priced at a discount to many other companies in its sector.

Simply Wall St also calculates a “Fair Ratio” for Innospec, which is the P/E multiple of about 17.3x that might be expected given its earnings growth profile, industry, profit margins, market cap and company specific risks. This Fair Ratio can be more informative than a straight comparison with peers or the broad industry, because those benchmarks may not share the same growth outlook, risk or profitability. Against this Fair Ratio, Innospec’s current P/E of 16.4x points to the stock being modestly undervalued on this metric.

Result: UNDERVALUEDNasdaqGS:IOSP P/E Ratio as at May 2026

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Innospec Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as a simple way for you to attach your own story about Innospec to hard numbers like expected revenue, earnings, margins and fair value. On Simply Wall St’s Community page, where millions of investors share these views, Narratives connect that story to a full forecast and fair value estimate that updates when fresh information such as earnings or news arrives. This allows you to compare fair value with the current share price to decide whether the stock looks attractive or stretched based on your assumptions. For example, one investor might build a Narrative close to the analysts’ fair value of about US$99.33 per share with revenue reaching about US$2.1b and earnings of roughly US$168.5m by 2029 on a P/E of about 17.6x. Another investor might set a lower fair value if they are more cautious on margins, sector risks or future demand for Innospec’s products.

Do you think there's more to the story for Innospec? Head over to our Community to see what others are saying!NasdaqGS:IOSP 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include IOSP.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments